AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
5don MSN
In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns ...
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
Humira sales in 2024 were $9 billion, down 58% from their peak. The good news is that AbbVie has already found a replacement for Humira with two blockbuster drugs: Skyrizi and Rinvoq. While these ...
AbbVie's positioning in this niche is intact thanks to its superstar products like Rinvoq, Skyrizi, and Humira. Humira has been dominating the space for almost two decades until its patent expired ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...
24/7 Wall St. on MSN6d
AbbVie Just Paid Investors: Here's How Much They ReceivedAbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback